Induction or Concurrent Chemotherapy and Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer
Thoracic radiation therapy was considered to be the standard care for patients with inoperable non-small cell lung cancer (NSCLC) in the United States for many years. Although the long-term results of such treatment were far from satisfactory (a large number of investigators reported approximately 1 patient of 20 treated survived 5 years), it was the only modality that offered any possibility of cure for patients with unresectable tumors. Over the past few years, combined chemotherapy and thoracic radiation therapy (TRT) have become standard treatment for patients with unresectable NSCLC if they have good performance status and minimal or no weight loss (SHAAKE-KONIG et al. 1992; DILLMAN et al. 1990; LECHEVALIER et al. 1991; SAUSE et al. 1995).
KeywordsInduction Chemotherapy Radiation Therapy Oncology Group Local Tumor Control Concurrent Chemotherapy Compare Radiation Therapy
Unable to display preview. Download preview PDF.
- Byhardt RW, Scott C, Sause WT et al. (1998) Response, toxicity failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 42:469–478.PubMedCrossRefGoogle Scholar
- Cox JD, Pajak TF, Asbell S et al. (1993) Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group trials. Int J Radiat Oncol Biol Phys 27:493–498.PubMedCrossRefGoogle Scholar
- Early Breast Cancer Trials Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1–15, 71–85.Google Scholar
- Furuse K, Fukuoka M, Takada Y et al. (1997) A randomized phase III study of concurrent versus sequential thoracic radiotherapy (TRT) in combination of mitomycin (M), vindesine (V), and cisplatin (P) in unresectable stage III non-small cell lung cancer (NSCLC): preliminary analysis. Proc Am Soc Clin Oncol 16:459a.Google Scholar
- Komaki R, Scott C, Ettinger D et al. (1997a) Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92–04. Int J Radiat Oncol Biol Phys 38:149–155.PubMedCrossRefGoogle Scholar
- Komaki R, Scott CB, Sause WT et al. (1997b) Induction cisplatin/vinblastine and irradiation vs irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88–08/ECOG 4588. Int J Radiat Oncol Biol Phys 39:537–544Google Scholar
- LeChevalier T, Arriagada R, Quoix E et al (1991) Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer. First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 93:417–423Google Scholar
- Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: metaanalysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311:899–909.Google Scholar
- Trovo MG, Minatel E, Veronesi A et al. (1990) Combined radiotherapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma. A randomized study. Cancer 65:400–404.Google Scholar
- Tubiana M, Frindel E, Malaise E (1968) The application of radiobiologie knowledge and cellular kinetics to radiation therapy. Am J Roentgen Rad Ther Nucl Med 102:822–830.Google Scholar